Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Gilead | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Gilead

HIV product sales were $4.1 billion in the quarter, up 21%

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Gilead
4Q Revenues: $5.8 billion (-2%)
4Q Earnings: $3 million (loss of $3.9 billion 4Q17)
FY Revenues: $22.1 billion (-15%)
FY Earnings: $5.5 billion (+18%)
Comments: Total product sales in the quarter were $5.8 billion, flat compared to 4Q17. Sales were $4.5 billion in the U.S., $813 million in Europe and $398 million in other locations. HIV product sales were $4.1 billion in the quarter, up 21%. Growth was primarily due to the launch of Biktarvy in 2018 and the continued uptake of Descovy, Genvoya and Odefsey. Chronic hepatitis C virus (HCV) product sales, which consist of Epclusa, Harvoni, Vosevi and Sovaldi, were $738 million in the quarter compared to $1.5 billion in 4Q17. Yescarta, which was launched in the U.S. in October 2017, generated $81 million in sales in the quarter. Other product sales, which include products from Gilead’s chronic hepatitis B virus (HBV), cardiovascular, oncology and other categories inclusive of Vemlidy, Viread, Letairis, Ranexa, Zydelig and AmBisome, were $797 million in the quarter, down 10%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters